EC Microbiology

Review Article Volume 19 Issue 4 - 2023

What Markers are Activated in Gut Dysbiosis?

Álvaro Zamudio Tiburcio1*, Héctor Bermúdez Ruiz2 and Silverio Alonso López3

1Department of Gastroenterology, Intestinal Microbiota Transplantation Medical Specialties Naples Unit, Mexico

2Endoscopy Service, Oncology Hospital, National Medical Center, XXI Century, Mexican Social Security Institute, Hospital Trinidad, Mexico City, Mexico

3Department of Urologist, Chairman Medical Specialties Naples in Mexico City, Mexico

*Corresponding Author:Álvaro Zamudio Tiburcio, Department of Gastroenterology, Intestinal Microbiota Transplantation Medical Specialties Naples Unit, Mexico.
Received: February 27, 2023; Published: March 17, 2023

Although new markers of gut dysbiosis appear every day, they continue to be a necessary find, since applying much more expensive studies, such as metagenomics and others, are not entirely consistent.

However, we should not disregard the clinic, as it is considered a stable instrument of medical assistance, since not all patients can afford and undergo through expensive studies. This is due to the lack of these medical practices worldwide and their tendency to stay in large research centers. Undoubtedly, making these processes more affordable is one of the priorities, in order to democratize the various genomic studies.

In this review we try to describe, even if briefly, a large number of markers, with the aim for them to be determined by users and used as excellent support in diagnosis, a crucial goal for caring for human health.

Keywords: Dysbiosis (Dys); Gut Dysbiosis (DG); Short Chain Fatty Acids (SCFA); Microbiome (Microb); Intestinal Microbiota (IM)

  1. Hegde S., et al. “Microbiota dysbiosis and its pathophysiological significance in bowel obstruction”. Scientific Reports 8 (2018): 13044.
  2. Toor D., et al. “Dysbiosis Disrupts Gut Immune Homeostasis and Promotes Gastric Diseases”. International Journal of Molecular Sciences 10 (2019): 2432.
  3. De Gruttola AK., et al. “Current understanding of Dysbiosis in disease in human and animal models”. Inflammatory Bowel Diseases 5 (2016): 1137-1150.
  4. Saltzman ET., et al. “Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease”. Frontiers in Microbiology 9 (2018): 61.
  5. Rea D., et al. “Microbiota effects on cancer: from risks to therapies”. Oncotarget 25 (2018): 17915-17927.
  6. Kump PK., et al. “Alteration of intestinal dysbiosis by fecal microbiota Transplantation does not induce remission in patients with chronic active Ulcerative colitis”. Inflammatory Bowel Diseases 10 (2013): 2155-2165.
  7. Vidal R., et al. “Diagnóstico y tratamiento del Déficit de alfa-1-antitripsina. Guidelines for the Diagnosis and Management of Alpha-1”. Archivos de Bonconeumología 12 (2006): 645-659.
  8. Carding S., et al. “Dysbiosis of the gut Microbiota in disease”. Microbial Ecology in Health and Disease 26 (2015): 26191.
  9. Blaser MJ. “Fecal Microbiota Transplantation for Dysbiosis - Predictable Risks”. The New England Journal of Medicine 381 (2019): 2064-2066.
  10. Gogokhia L., et al. “Intestinal Dysbiosis and Markers of Systemic Inflammation in Viscerally and Generally Obese Persons Living With HIV”. Journal of Acquired Immune Deficiency Syndromes 1 (2020): 81-89.
  11. Sugawara Y., et al. “Association of gut microbiota and inflammatory markers in obese patients with type 2 diabetes mellitus: post hoc analysis of a synbiotic interventional Study”. Biosci Microbiota Food Health 3 (2022): 103-111.
  12. Yu L., et al. “A systematic review of microbial markers For risk prediction of colorectal neoplasia”. British Journal of Cancer 126 (2022): 1318-1328.
  13. Dambrova M., et al. “Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials”. Pharmacological Reviews 3 (2022): 506-551.
  14. Chattopadhyay I., et al. “Interplay between Dysbiosis of Gut Microbiome, Lipid Metabolism, and Tumorigenesis: Can Gut Dysbiosis Stand as a Prognostic Marker in Cancer? ” Review Article (2022).
  15. Shaw KA., et al. “Dysbiosis, inflammation, and Response to treatment: a longitudinal study of pediatric subjects with Newly diagnosed inflammatory bowel disease”. Genome Medicine 75 (2016).
  16. Liu Y and Dai M. “Trimethylamine N-Oxide Generated by the Gut Microbiota Is Associated with Vascular Inflammation: New Insights Into Atherosclerosis”. Mediators of Inflammation (2020): 4634172.
  17. Kuo SZ., et al. “Associations between urinary 3-indoxyl sulfate, a gut microbiome-derived biomarker, and patient Outcomes after intensive care unit admission”. The Journal of Critical Care 63 (2021): 15-21.
  18. Pallister T., et al. “Hippurate As a metabolomic marker of gut microbiome diversity: Modulation by Diet and relationship to metabolic syndrome”. Scientific Reports 1 (2017): 13670.
  19. National Institutes of Health. NATIONAL LIBRARY OF MEDICINE. National Center for Biotechnology Information. Sodium benzoate (2021).
  20. De Palma G., et al. “Intestinal dysbiosis and reduced Immunoglobulin-coated bacteria associated with coeliac disease in Children”. BMC Microbiology 10 (2010): 63.
  21. Berlanga RN., et al. “Revista Sanitaria De Investigación”. La Zonulina como marcador de permeabilidad Intestinal 8 (2023).
  22. Gryp T., et al. “p-Cresyl Sulfate”. Toxins2 (2017): 52.
  23. Ortiz Casillas MI., et al. “Defensinas humanas y su Función en cavidad oral”. REVista MEXicana DE PERIODONTO Logía 3 (2019): 77-83.
  24. Gkolfinopoulos S., et al. “Chromogranin A as a valid marker in oncology: Clinical application or false hopes?” World Journal of Methodology 1 (2017): 9-15.
  25. Lord RS and Bralley JA. “Alternative Medicine Review Review Article Page 292 Clinical Applications of Urinary Organic Acids. Part 2”. Dysbiosis Markers 4(2008): 292.
  26. National Institutes of Health. National Library of Medicine. National Center of Biotechnology Information. 4- Hidroxybenzoato (2021).
  27. Kho ZY and Lal SK. “The Human Gut Microbiome - A Potential Controller of Wellness and Disease”. Frontiers in Microbiology 9 (2018): 1835.
  28. Majamaa H., et al. “Eosinophil protein X and eosinophil Cationic protein as indicators of intestinal inflammation in infants with atopic Eczema food allergy”. Clinical and Experimental Allergy 11 (1999): 1502-1506.
  29. Frost F., et al. “The Gut Microbiome in Patients with Chronic Pancreatitis Is Characterized by Significant Dysbiosis and Overgrowth By Opportunistic Pathogens”. Clinical and Translational Gastroenterology 9 (2020): e00232.
  30. Vidal R., et al. “Diagnóstico y tratamiento del Déficit de alfa-1-antitripsina. Guidelines for the Diagnosis and Management of Alpha-1”. Archivos de Bronconeumología 12 (2006): 645-659.
  31. Gloux K and Anba-Mondoloni J. “Unique β-Glucuronidase Locus in Gut Microbiomes of Crohn's Disease Patients and Unaffected First- Degree Relatives”. PLoS One 1 (2016): e0148291.
  32. Hrncirova L., et al. “Food Preservatives Induce Proteobacteria Dysbiosis in Human-Microbiota Associated Nod2-Deficient Mice”. Microorganisms 10 (2019): 383.

Álvaro Zamudio Tiburcio., et al. “What Markers are Activated in Gut Dysbiosis?”. EC Microbiology  19.4 (2023): 16-21.